Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (27)
Zhenisgul Tlegenova, Saule Balmagambetova, Bekbolat Zholdin, Gulnara Kurmanalina, Iliada Talipova, Arip Koyshybaev, Gulmira Sultanbekova, Mira Baspayeva, Saule Madinova, Kulparshan Kubenova, Aiganym Amanova & Amin Tamadon. (2023) Role of Clinical Risk Factors and B-Type Natriuretic Peptide in Assessing the Risk of Asymptomatic Cardiotoxicity in Breast Cancer Patients in Kazakhstan. Diagnostics 13:23, pages 3557.
Crossref
Crossref
Holger N. Lode, Ruth Ladenstein, Sascha Troschke-Meurer, Linda Struppe, Nikolai Siebert, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Evgenia Glogova, Patrick Hundsdoerfer, Angelika Eggert, Anna Zaniewska-Tekieli, Walentyna Balwierz & Aleksandra Wieczorek. (2023) Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy. Cancers 15:13, pages 3364.
Crossref
Crossref
Hanieh Kazemnian & Hassan Mehrad-Majd. (2023) Recent advances in the Prevention and Treatment of Chemotherapy–induced Cardiotoxicity. Research in Biotechnology and Environmental Science 2:2, pages 24-29.
Crossref
Crossref
Xuan Chen, Yuqing Li, Mingfei Lin & Yufu Lu. (2023) Efficacy and safety of treatment with or without pertuzumab for HER2-positive breast cancer: A meta-analysis. Medicine 102:22, pages e33925.
Crossref
Crossref
Joanna d’Arc Lyra Batista, Rafael José Vargas Alves, Taís Belladona Cardoso, Marcelo Moreno, Katsuki Arima Tiscoski & Carisi Anne Polanczyk. (2023) Effectiveness of adjuvant trastuzumab in women with HER-2+ breast cancer in the SUS. Ciência & Saúde Coletiva 28:6, pages 1819-1830.
Crossref
Crossref
Joanna d’Arc Lyra Batista, Rafael José Vargas Alves, Taís Belladona Cardoso, Marcelo Moreno, Katsuki Arima Tiscoski & Carisi Anne Polanczyk. (2023) Efetividade do Trastuzumabe adjuvante em mulheres com câncer de mama HER-2+ no SUS. Ciência & Saúde Coletiva 28:6, pages 1819-1830.
Crossref
Crossref
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan & Maarten Jacobus Postma. (2023) Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis. Frontiers in Pharmacology 14.
Crossref
Crossref
Zhijie Huang, Xiaoxia Yang, Yisheng Huang, Zhengming Tang, Yuanxin Chen, Hongyu Liu, Mingshu Huang, Ling Qing, Li Li, Qin Wang, Zhuye Jie, Xin Jin & Bo Jia. (2023) Saliva – a new opportunity for fluid biopsy. Clinical Chemistry and Laboratory Medicine (CCLM) 61:1, pages 4-32.
Crossref
Crossref
Junyoung Shin, Baknoon Ham, Jeong-Han Seo, Sae Byul Lee, In Ah Park, Gyungyub Gong, Sung-Bae Kim & Hee Jin Lee. (2023) Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer. Therapeutic Advances in Medical Oncology 15, pages 175883592311576.
Crossref
Crossref
Hoon Jai Chun, Seun Ja Park, Yun Jeong Lim & Si Young SongHoon Jai Chun, Seun Ja Park, Yun Jeong Lim & Si Young Song. 2023. Gastrointestinal Cancer. Gastrointestinal Cancer
57
61
.
A. A. Semenkin, V. S. Sapronenko, E. N. Loginova & E. V. Nadey. (2022) Targeted therapy in oncology. Experimental and Clinical Gastroenterology:9, pages 222-228.
Crossref
Crossref
Yan Lu, Aaron W. Gehr, Ifedioranma Anikpo, Rachel J. Meadows, Kevin J. Craten, Kalyani Narra, Anuradha Lingam, Sandeep Kamath, Bhavna Tanna, Bassam Ghabach & Rohit P. Ojha. (2022) Cardiotoxicity among socioeconomically marginalized breast cancer patients. Breast Cancer Research and Treatment 195:3, pages 401-411.
Crossref
Crossref
Thalita Basso Scandolara, Bruno Ricardo Barreto Pires, Beatriz Vacario, Isis Salviano Soares de Amorim, Priscyanne Barreto Siqueira, Juliana Mara Serpeloni, André Luiz Mencalha, Cibele Rodrigues Bonvicino & Carolina Panis. (2022) An Overview Regarding Pharmacogenomics and Biomarkers Discovery:
Focus on Breast Cancer. Current Topics in Medicinal Chemistry 22:20, pages 1654-1673.
Crossref
Crossref
Yarely M. Salinas-Vera, Jesús Valdés, Yussel Pérez-Navarro, Gilberto Mandujano-Lazaro, Laurence A. Marchat, Rosalio Ramos-Payán, Stephanie I. Nuñez-Olvera, Carlos Pérez-Plascencia & César López-Camarillo. (2022) Three-Dimensional 3D Culture Models in Gynecological and Breast Cancer Research. Frontiers in Oncology 12.
Crossref
Crossref
Yufei Ma, Weidong Li, Kai Ma, Tianyun Wang & Huigen Feng. (2022) Cell Surface Markers and their Targeted Drugs in Breast Cancer. Current Protein & Peptide Science 23:5, pages 335-346.
Crossref
Crossref
Khalid Al‑Saleh, Ahmed Abdel‑Warith, Mohammed Alghamdi, Abdurrahman Aldiab, Arwa Ali, Eyad Alsaeed, Waleed Abozeed & Nashwa Abdel‑aziz. (2022) Incidence of trastuzumab‑induced cardiotoxicity and impact of body mass index in patients with breast cancer: Results from a Saudi tertiary cancer center. Molecular and Clinical Oncology 16:4.
Crossref
Crossref
Huan Wang, Peter Donnan, E. Jane Macaskill, Lee Jordan, Alastair Thompson & Andy Evans. (2022) A pre-operative prognostic model predicting all cause and cause specific mortality for women presenting with invasive breast cancer. The Breast 61, pages 11-21.
Crossref
Crossref
Christoph Thomssen. (2021) Prädiktive und prognostische Faktoren in der Therapie des frühen MammakarzinomsPredictive and prognostic factors in the treatment of early breast cancer. Der Onkologe 27:12, pages 1175-1190.
Crossref
Crossref
Huiyu Xiao, Xiaojie Wang, Shuang Li, Ying Liu, Yijie Cui & Xiaoqin Deng. (2021) Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Amsalu Degu & Asha Yussuf. (2021) Treatment outcomes among human epidermal growth factor receptor 2 positive breast cancer patients: A systematic review. Journal of Oncology Pharmacy Practice 27:6, pages 1468-1476.
Crossref
Crossref
Daniel Lapirow, Andre La Gerche, Claudia Toro, Emma Masango, Ben Costello, Enzo Porello, Louise Ludlow, Glenn Marshall, Toby Trahair, Marion Mateos, Jeremy Lewin, Jennifer Byrne, Rose Boutros, Rebecca Manudhane, John Heath, Julian Ayer, Melissa Gabriel, Thomas Walwyn, Jelena Saundankar, Jonathon Forsey, Ha Le, Kylie Mason, David Celermajer, Peter Downie, Roderick Walker, Lucy Holland, Michelle Martin, Lorna McLeman, Yonatan Diamond, Maurizio Marcocci, Susan Donath, Michael Cheung, David A. Elliott & Rachel Conyers. (2021) The Australia and New Zealand Cardio‐Oncology Registry: evaluation of chemotherapy‐related cardiotoxicity in a national cohort of paediatric cancer patients. Internal Medicine Journal 51:2, pages 229-234.
Crossref
Crossref
Francesco Sabbatino, Valeria Conti, Luigi Liguori, Giovanna Polcaro, Graziamaria Corbi, Valentina Manzo, Vincenzo Tortora, Chiara Carlomagno, Carmine Vecchione, Amelia Filippelli & Stefano Pepe. (2021) Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients. Life 11:2, pages 105.
Crossref
Crossref
Rahul Kulkarni, Shriniwas Kulkarni, Almas Pathan & Shona Nag. (2021) A Retrospective analysis of biosimilar and reference trastuzumab in human epidermal growth factor receptor-2 positive early and/or locally advanced breast cancer patients treated with neoadjuvant-adjuvant setting: Safety and event-free survival outcomes. Oncology Journal of India 5:3, pages 97.
Crossref
Crossref
Marina T Van Leeuwen, Steven Luu, Howard Gurney, Martin R Brown, Sallie-Anne Pearson, Kate Webber, Lee Hunt, Soojung Hong, Geoffrey P Delaney & Claire M Vajdic. (2020) Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews. JNCI Cancer Spectrum 4:6.
Crossref
Crossref
Qiancheng Hu, Xin Wang, Ye Chen, Xiaofen Li, Ting Luo & Dan Cao. (2020) Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ Open 10:11, pages e035802.
Crossref
Crossref
Laura Orlando, Vito Lorusso, Francesco Giotta, Massimo Di Maio, Paola Schiavone, Palma Fedele, Annamaria Quaranta, Chiara Caliolo, Mariangela Ciccarese, Margherita Cinefra, Sante Romito, Salvatore Pisconti, Salvatore del Prete, Michele Aieta, Daniele Rizzi, Evaristo Maiello, Giuseppe Colucci & Saverio Cinieri. (2020) Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). The Breast 53, pages 18-22.
Crossref
Crossref
Ke-Da Yu, Xin Wang, Wan-Kun Chen, Lei Fan, Miao Mo & Han Chen. (2020) Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer. npj Precision Oncology 4:1.
Crossref
Crossref